Abstract
CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have